Drug class
Fibroblast growth factor receptor (FGFR) 1-3 tyrosine kinase inhibitor; targeted antineoplastic (withdrawn US indication)
Mechanism of action
Inhibits FGFR1, FGFR2 and FGFR3 tyrosine kinase activity, reducing downstream signalling in tumours driven by susceptible FGFR alterations.
General use cases
- Historical US indication: treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement. US approval of Truseltiq was withdrawn 16 May 2024; do not list as a current US-authorised treatment.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
